Abstract
The aim of this study was to assess the results of high-dose radioiodine therapy given to 43 patients with recurrent hyperthyroidism due to Graves' disease between 1986 and 1992. We chose an intrathyroidal absorbed dose of 300 Gy and determined the applied activity individually, which ranged from 240 to 3120 MBq with a median of 752 MBq. Hyperthyroidism was eliminated in 86% of cases after 3 months and in 100% after 12 months. No patient required a second radioiodine treatment. The incidence of hypothyroidism was 63% after 3 months and 93% after 18 months. Neither the pretherapeutic thyroid-stimulating immunoglobulin level nor the degree of co-existing endocrine ophthalmopathy was correlated with the time at which hypothyroidism developed. Patients with previous radioiodine therapy developed hypothyroidism earlier than patients with previous thyroid surgery. The results show that ablative radioiodine therapy with a 300-Gy absorbed dose is a very effective treatment of hyperthyroidism in Graves' disease, but it should be restricted to patients with recurrent hyperthyroidism combined with severe co-existing disorders or episodes of unfavourable reactions to antithyroid drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reiners C. Aktuelle Gesichtspunkte zur Radiojodbehandlung der Hyperthyreose vom Typ des M. Basedow. Akt Endokr Stoffw 1989;10: 125–132
Moser E, Pickardt CR, Mann K, Engelhardt D, Kirsch CM, Knesewitsch P, Tatsch K, Kreisig T, Kurz C, Saller B. Ergebnisse der Radiojodbehandlung von Patienten mit immunogener und nicht-immunogener Hyperthyreose bei Anwendung unterschiedlicher Herddosen. Nucl-Med 1988;27: 98–104
Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes. II. Practical considerations in therapy and protection. Am J Roentgenol 1948;59: 260–281
Wise PH, Ahmad A, Burnet RB, Harding PE. Intentional radioiodine ablation in Graves' disease. Lancet 1975;2: 1231–1233
Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J 1984;289: 361–363
Hamburger JI. Intentional radioiodine ablation in Graves' disease. Lancet 1976;I: 492
Safa AM, Skillem PG. Treatment of hyperthyroidism with a large initial dose of sodium iodide I 131. Arch Intern Med 1975;135: 673–675
Goolden AWG, Stewart JSW. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol 1986;24: 217–222
Douglas JG. The Vanderbilt experience with I 131 treatment for Graves' disease. South Med J 1973;66: 92–94
Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982;23: 103–107
Nofall MM, Beierwaltes WH, Patno ME. Treatment of hyperthyroidism with sodium iodide I 131. A 16-year experience. JAMA 1966;197: 605–610
Sridama V McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose I311 therapy for Graves' disease. N Engl J Med 1984;311: 426–432
Alevizaki CC, Alevizaki-Harhalaki MC, Ikkos DG. Radioiodine-131 treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism. Eur J Nucl Med 1985;10: 450–454
Goolden AW, Davey JB. The ablation of normal thyroid tissue with iodine 131. Br J Radiol 1963;36: 340–345
Ratcliffe GE, Fogelman I, Maisey MN. The evaluation of radioiodine therapy for thyroid patients using a fixed-dose regimen. Br J Radiol 1986;59: 1105–1107
Reid DJ. Hyperthyroidism and hypothyroidism complicating the treatment of thyrotoxicosis. Br J Surg 1987;74: 1060–1062
Scott GR, Forfar JC, Toft AD. Graves' disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131. Br Med J 1984;289: 399–400
Reiners C, Peters H, Fischer C, Schleusener H. Results of a German multicentric study on radioiodine treatment of Graves' hyperthyroidism with a standard activity of 550 MBq versus an individually calculated dose of 100 Gy. In: Schmidt HAE, Höfer R, eds. Nuclear medicine: nuclear medicine in research and practice. Stuttgart New York: Schattauer; 1992: 719–722
Author information
Authors and Affiliations
Additional information
Correspondence to: U.F. Willemsen
Rights and permissions
About this article
Cite this article
Willemsen, U.F., Knesewitsch, P., Kreisig, T. et al. Functional results of radioiodine therapy with a 300-GY absorbed dose in Graves' disease. Eur J Nucl Med 20, 1051–1055 (1993). https://doi.org/10.1007/BF00173482
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00173482